Lebrikizumab for Atopic Dermatitis
This trialtests a drug to treat atopic dermatitis, a common skin condition, in teens and adults, especially in people with skin of color.
- Atopic Dermatitis
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 3 trial • 424 Patients • NCT04146363
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
To what degree does Lebrikizumab present a risk to individuals?
"The safety of Lebrikizumab is rated a 3, indicating that there has been preceding evidence to demonstrate its efficacy and multiple evaluations in favor of the drug's security."
Does this research endeavor currently accept new enrollees?
"Investigation of clinicaltrials.gov reveals that this medical trial is not enrolling patients at the current moment, having been posted on December 15th 2022 and last updated on December 7th 2022. Fortunately, there are an additional 237 studies currently recruiting participants."